Drugs / Infanrix™-IPV+Hib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01309646 | Mar 2011 → Feb 2012 | diphtheria, haemophilus infectious disease, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Infanrix-IPV+Hib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01309646 ↗ |
| Known as | DTPa-IPV/Hib | “Immunogenicity and Safety of GlaxoSmithKline Biologicals' DTPa-IPV/Hib (Infanrix™-IPV+Hib) Vaccine in Healthy Korean Infants” NCT01309646 ↗ |
| Modality | Vaccine | “Infanrix™-IPV+Hib Vaccine” NCT01309646 ↗ |
| Route | Intramuscular | “The Infanrix™-IPV+Hib was administered intramuscularly” NCT01309646 ↗ |